{"id":266344,"date":"2026-09-24T10:31:11","date_gmt":"2026-09-24T05:01:11","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=266344"},"modified":"2026-09-24T10:31:11","modified_gmt":"2026-09-24T05:01:11","slug":"beta-drugs-best-stock-in-its-sector","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/beta-drugs-best-stock-in-its-sector\/","title":{"rendered":"Is Beta Drugs the Best Stock in Its Sector? A Look at the Numbers"},"content":{"rendered":"

Beta Drugs CMP Rs 2,188 (24 Sep 2026). Market cap Rs 2,425 Cr. ROE 16.95%. P\/E 52.41x versus Industry P\/E 38.33x.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Beta Drugs is one of the names investors compare when screening the Healthcare sector, built on a 16.95% return on equity and a P\/E of 52.41x against an Industry P\/E of 38.33x. Whether Beta Drugs is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.<\/p>\n<\/p><\/div>\n

Is Beta Drugs<\/a> the best stock in its sector? The stock trades on the NSE at Rs 2,188 as of 24 September 2026, within its 52-week range of Rs 990.10 to Rs 2,807.90. Beta Drugs Ltd manufactures oncology and specialty injectable pharmaceutical formulations.<\/p>\n

Beta Drugs sits in the Healthcare sector, and its 16.95% ROE and 52.41x P\/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P\/E benchmark.<\/p>\n

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers<\/a><\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n